Displaying drugs 14376 - 14400 of 14508 in total
CRx-139
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
Matched Description: … The synergistic combination containing low doses of the glucocorticoid steroid prednisolone and the antidepressant …
2-(4-HYDROXY-3-NITROPHENYL)ACETIC ACID
Experimental
Rivoglitazone
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
Experimental
Investigational
4SC-203
4SC-203 has been used in trials studying the treatment of Acute Myeloid Leukemia.
Investigational
Hexamethonium
A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by...
Experimental
Matched Description: … It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. …
Sorbinil
Experimental
Investigational
GI-181771X
Gski181771 X is under investigation in clinical trial NCT00600743 (Effect of a CCK-1R Agonist on Food Intake in Humans).
Investigational
Nifurpirinol
Experimental
Vet approved
Ondelopran
Ondelopran has been used in trials studying the treatment of Alcohol Dependence.
Investigational
Debromohymenialdisine
Experimental
CTS-21166
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and …
Displaying drugs 14376 - 14400 of 14508 in total